Myelodysplastic Syndrome Clinical Trial

Clinical Trial Finder Myelodysplastic Syndrome Trials

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

See Locations Near You

Summary

The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).

View Full Description

Full Description

Phase I: The purpose of this study was to determine which of the subcutaneous doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS

Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of the study.

Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due to a change in product development strategy

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Confirmed diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia (CMML).

Exclusion Criteria:

Prior therapy with decitabine or azacytidine (Vidaza).
Experimental or standard drugs for the treatment of MDS within 28 days of the first day of study drug treatment.
Clinically significant anemia.
Prior history of malignancy other than MDS.
Any active infection.
Radiotherapy within 14 days prior to study enrollment.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

41

Study ID:

NCT00282399

Recruitment Status:

Terminated

Sponsor:

Eisai Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

University of Arizona Cancer Center
Tucson Arizona, 85724, United States
H Lee Moffitt Cancer Center & Research Institute
Tampa Florida, 33612, United States
Albert Einstein College of Medicine
Bronx New York, 10461, United States

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

41

Study ID:

NCT00282399

Recruitment Status:

Terminated

Sponsor:


Eisai Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider